Skip to content
10-Q

Quarterly Report

Treace Medical Concepts, Inc. TMCI

0001193125-26-213322

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 64.87M sh
Shares Diluted Q1 2026 · Mar 31, 2026 64.59M sh
Shares Diluted Q1 2026 · Mar 31, 2025 62.66M sh
Capex Q1 2026 · Mar 31, 2026 $3.06M
Capex Q1 2026 · Mar 31, 2025 $3.54M
Operating Cash Flow Q1 2026 · Mar 31, 2026 $7.24M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $4.2M
Long Term Debt Q1 2026 · Mar 31, 2026 $55.82M
Long Term Debt Q1 2026 · Dec 31, 2025 $55.58M
Short Term Debt Q1 2026 · Mar 31, 2026 $1.78M
Short Term Debt Q1 2026 · Dec 31, 2025 $1.75M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $9.54M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $10.71M
Stockholders Equity Q1 2026 · Mar 31, 2026 $77.19M
Stockholders Equity Q1 2026 · Dec 31, 2025 $87.33M
Stockholders Equity Q1 2026 · Mar 31, 2025 $105.34M
Stockholders Equity Q1 2026 · Dec 31, 2024 $112.89M
Current Liabilities Q1 2026 · Mar 31, 2026 $34.49M
Current Liabilities Q1 2026 · Dec 31, 2025 $30.64M
Total Liabilities Q1 2026 · Mar 31, 2026 $106.91M
Total Liabilities Q1 2026 · Dec 31, 2025 $103.25M
Current Assets Q1 2026 · Mar 31, 2026 $123.47M
Current Assets Q1 2026 · Dec 31, 2025 $132.05M
Total Assets Q1 2026 · Mar 31, 2026 $184.1M
Total Assets Q1 2026 · Dec 31, 2025 $190.58M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.28
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.25
Eps Basic Q1 2026 · Mar 31, 2026 −$0.28
Eps Basic Q1 2026 · Mar 31, 2025 −$0.25
Sga Expense Q1 2026 · Mar 31, 2026 $16.18M
Sga Expense Q1 2026 · Mar 31, 2025 $15.79M
Rd Expense Q1 2026 · Mar 31, 2026 $4.62M
Rd Expense Q1 2026 · Mar 31, 2025 $5.56M
Net Income Q1 2026 · Mar 31, 2026 −$17.96M
Net Income Q1 2026 · Mar 31, 2025 −$15.92M
Operating Income Q1 2026 · Mar 31, 2026 −$17.17M
Operating Income Q1 2026 · Mar 31, 2025 −$15.58M
Gross Profit Q1 2026 · Mar 31, 2026 $37.41M
Gross Profit Q1 2026 · Mar 31, 2025 $41.89M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $9.79M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $10.68M
Revenue Q1 2026 · Mar 31, 2026 $47.2M
Revenue Q1 2026 · Mar 31, 2025 $52.57M